PDF(Pubmed)
Abstract：
V-set domain-containing T-cell activation inhibitor 1 (aliases VTCN1, B7H4) participates in tumour immune escape by delivering inhibitory signals to T cells. The purpose of this article was to assess the B7H4 prognostic value in solid cancers. Three databases were searched for relevant articles. The main endpoints were overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), recurrence-free survival (RFS), and disease-free survival (DFS). Appropriate hazard ratios (HRs) were pooled. The R studio software (version 4.0.3) was used for data analysis. Thirty-one studies met the inclusion criteria. High expression of B7H4 was associated with worse OS (HR = 1.52, 95% CI: 1.37-1.68) but not with DSS (HR = 1.14, 95% CI: 0.49-2.63), RFS (HR = 1.77, 95% CI: 0.75-4.18), DFS (HR = 1.29, 95% CI: 0.8-2.09), or PFS (HR = 1.71, 95% CI: 0.91-3.2) in patients with solid cancers. High expression of B7H4 is associated with a poorer prognosis in patients with solid cancers. B7H4 is a promising prognostic biomarker and immunotherapeutic target for various solid cancers because of its activity in cancer immunity and tumourigenesis.
摘要：
含有V集结构域的T细胞活化抑制剂1(别名VTCN1、B7H4)通过向T细胞递送抑制信号而参与肿瘤免疫逃逸。本文的目的是评估B7H4在实体癌中的预后价值。检索了三个数据库中的相关文章。主要终点是总生存期（OS），疾病特异性生存率（DSS），无进展生存期（PFS），无复发生存率（RFS），无病生存率（DFS）。合并适当的风险比(HR)。使用R工作室软件(4.0.3版)进行数据分析。31项研究符合纳入标准。B7H4的高表达与OS恶化有关（HR=1.52，95％CI：1.37-1.68），但与DSS无关（HR=1.14，95％CI：0.49-2.63），RFS（HR=1.77，95%CI：0.75-4.18），DFS（HR=1.29，95%CI：0.8-2.09），实体癌患者的PFS（HR=1.71，95%CI：0.91-3.2）。B7H4的高表达与实体癌患者预后较差有关。由于B7H4在癌症免疫和肿瘤发生中的活性，因此B7H4是各种实体癌的有前途的预后生物标志物和免疫治疗靶标。
